By Ben Glickman

Amgen has received priority review status from the Food and Drug Administration for its biologics license application for a small cell lung cancer treatment.

The Thousand Oaks, Calif.-based pharmaceutical company will get an answer from the FDA on its application in six months, instead of the typical 10 months.

Amgen's BLA is for tarlatamab, a treatment for advanced small cell lung cancer with disease progression on or after platinum-based chemotherapy.

The application is based on the results from a Phase 2 study.

Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

December 13, 2023 16:25 ET (21:25 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024 Amgen 차트를 더 보려면 여기를 클릭.
Amgen (NASDAQ:AMGN)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024 Amgen 차트를 더 보려면 여기를 클릭.